Halal is not merely an obligation—it is the foundation of trust. From there, quality is reflected and built. As Indonesia approaches the mandatory halal implementation in 2026, Dexa Group is taking concrete steps to ensure every process remains compliant while embodying trusted quality.

In line with this commitment, Dexa Group’s Halal Committee has taken decisive action by strengthening collaboration and aligning strategies to prepare for the national halal policy implementation. This was realized through an official visit to the Assessment Institute for Foods, Drugs, and Cosmetics of the Indonesian Ulema Council (LPPOM MUI) in Bogor on Thursday (April 2, 2026).

Carrying the theme *“Dexa Group & LPPOM Gathering,”* the visit served as a meaningful opportunity to deepen synergy while opening strategic discussions on the evolving halal regulatory landscape—particularly ahead of the mandatory implementation in October 2026.

The Dexa Group Halal Committee delegation was warmly welcomed by the Commercial and Partnership Director of LPPOM MUI, Dr. Ir. Muslich, M.Si. In his remarks, he shared strategic insights on the importance of synergy between the pharmaceutical industry and all relevant stakeholders in preparing for the October 2026 mandate.

Industry Readiness for Halal Implementation

Mr. Muslich emphasized that industry readiness goes beyond documentation compliance. It must also include robust systems, competent human resources, and the strengthening of the halal supply chain end-to-end.

He also outlined several strategic recommendations, including the importance for pharmaceutical companies to be truly “ready” in meeting halal certification requirements, reinforcing supply chain management—particularly across suppliers and vendors—and accelerating broader, more structured outreach on mandatory halal implementation.

The strong enthusiasm of Dexa Group’s Halal Committee was evident through interactive discussions covering various technical aspects and best practices in halal implementation within the pharmaceutical sector.

On the same occasion, Dexa Group’s Corporate Quality Management Director and Chairman of the Halal Committee, Mr. Effendi, reaffirmed that synergy in implementing the Halal Product Assurance System (SJPH) is essential.

He added that the purpose of the visit was to provide participants with a grounded understanding of the current landscape and challenges of halal regulatory implementation in Indonesia—directly from the perspective of a halal inspection body.

Through this initiative, Dexa Group reinforces its commitment to remain at the forefront of halal standard implementation in Indonesia’s pharmaceutical industry. This commitment goes beyond regulatory compliance—it is about elevating the quality and global competitiveness of Indonesian pharmaceutical products.

As the October 2026 deadline approaches, collaboration with LPPOM MUI becomes increasingly critical. Moving forward, this synergy will continue to be strengthened through open communication, knowledge exchange, and ongoing innovation.

Because ultimately, halal is not just about compliance—it is about building trust that lasts.